Pegylated Liposomal Doxorubicin: Antitumor Activity in Epithelial Ovarian Cancer or Cancers of Peritoneal Origin

ONCOLOGY

Volumn 11, Issue 10 SUPPL. 12, 1997, Pages 38-44

  Muggia, Franco M ^a   Safra, Tamar ^d   Groshen, Susan ^d   Jeffers, Susan ^d   Lynda Roman, R N ^d   Tan, Matthew ^d   Muderspach, Laila ^d   Burnett, Alexander ^d   Formenti, Silvia ^d   Paul Morrow, C ^b   Amantea, Michael ^c  

^a NEW YORK UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c ALZA CORPORATION   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CIMETIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LIPOSOME; PACLITAXEL;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; STOMATITIS; VOMITING;

EID: 0030828846     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Kruskal JB, Cay O, Thomas P, et al. 'Stealth Liposomes'. A promising agent for targeting hepatic colorectal cancer metastases (Suppl). Radiology 201:320, 1996.
2. Papahadjopoulos D, Allen TM, Gabizon A, et al: Stencally stabilized liposomes: Improvements in pharmacokinetics and anti-tumor therapeutic efficacy. Proc Natl Acad Sci 88:11460-11464, 1991.
3. Huang SK, Mayhew E, Gilani S, et al. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 52:6774-6781, 1992.
4. Vaage J, Barbera-Guillem E, Abra R, et al: Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 73:1478-1484, 1994.
5. Williams S, Alosco T, Mayhew E, et al: Arrest of human lung tumor xenograft in severe combined immunodeficient mice using doxorubicin in AIDS-related Kaposi's sarcoma. Lancet 53:3964-3967, 1993.
6. Vaage J, Donovan D, Mayhew E Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes- Cancer 72:3761-3765, 1993.
7. Uziely B, Gabizon A, Jeffers S, et al: Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13:1777-1785, 1995.
8. Muggia FM, Hainsworth JD, Jeffers S, et al: Phase II study of liposomal doxorubicin (Doxil) in epithelial ovarian cancer. Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993, 1997.
9. Huang SK, Stauffer PR, Hong K, et al: Liposomes and hyperthermia in mice: Increased tumor uptake, and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res 54:2186-2191, 1994
10. Green S, Weiss G: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992.
11. Rustin GJS, Nelstrop AE, McClean P, et al: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14:1545-1551, 1996.
12. Safra T, Jeffers S, Groshen S, et al: Doxil in ovarian cancer: summary of experience in three consecutive phase I/II studies (abstract 1248). Proc Amer Soc Clin Oncol 16:349a, 1997.
13. Israel VK, Jeffers S, Bernal S, et al: Phase I study of Doxil (liposomal doxorubicin) in combination with paclitaxel (abstract 842). Proc Amer Soc Clin Oncol 16:239a, 1997.
14. Garcia AA, Muggia FM: Activity of anthracyclines in refractory ovarian cancer: recent experience and review. Cancer Invest 15:329-334, 1997.